Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Jan 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in melanoma, sponsored by SWOG Cancer Research Network. Started Jan 2021; status: recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04511013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511013.